CSI Market
Sign In | Register

China Biologic Products Holdings Inc (CBPO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CBPO Annual Cash Flow →
This page allows investors to follow China Biologic Products Holdings Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2019)
12 Months 		0 0 0 (Dec 31 2018)
Operating Activities
Income138.81
Depreciation & amortization16.52
Amortization of Other Assets9.72
Increase (Decrease) in Deferred Revenue0.00
Other Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories14.85
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total-0.30
Share-based Compensation26.60
Income (Loss) from Equity Method Investments1.59
Financial Instruments and Foreign Currency Transaction0.00
Impaired Assets To Be Disposed Of By Method Other Than Sale Amount Of Impairment Loss-
Allowance For Loan And Lease Losses Recoveries Of Bad Debts-
Reversal Of Provision For Doubtful Accounts Other Receivables And Prepayments-
Gain Loss On Derivative Instruments Net Pretax-
Amortization Of Deferred Charges-
Debt Instrument Convertible Interest Expense-
Increase Decrease In Accrued Interest Noncontrolling Interest Shareholders-
Provision For Reversal Of Allowance For Doubtful Accounts Accounts Receivable Net-
Allowance For Loan And Lease Loss Recovery Of Bad Debts-
Acquisition Of Property Plant And Equipment Included In Payables-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Income taxes-2.44
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities-22.13
Increase (Decrease) in Accounts Payable-1.30
Accrued Expense0.00
Increase (Decrease) in Customer Deposits0.00
Increase (Decrease) in Prepaid Expense-4.40
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net24.59
Payments for (Proceeds from) Other Operating Activities41.07
Discontinued operations0.00
Net Cash flow from Operating Activities229.34
Investing Activities
Capital Expenditures0.15
Sale of Capital Items4.56
Short-term Investments Proceeds924.06
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment Related To L and Used Right-
Refund Of Deposits Related To L and Use Right-
Proceeds Upon Maturity Of Time Deposit-
Proceeds From Government Grants Related To Property And Equipment-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Payments to Acquire Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-155.86
Discontinued operations0.00
Net Cash Flow from Investing Activities-180.14
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock118.95
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-229.47
Repayments Of Noncontrolling Interest Shareholder Loan-
Payment For Deposit As Security For Long Term Bank Loans-
Payments Of Dividend To Trial Court To Be Held In Escrow As To Dispute With Jiean-
Payments of Ordinary Dividends, Noncontrolling Interest10.12
Dividends paid0.00
Net Cash Flow from Financing Activities-229.47
Effect of exchange rate on cash flow3.14
Discontinued operations0.00
Free Cash Flow234.05
Total Cash Flow-177.13
4 historic quarters locked

Sign in to unlock the full China Biologic Products Holdings Inc cash flow history.

Sign In Create Free Account

About CBPO Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.